Organonitrogen Compounds
Medchemexpress LLC TO-1187 (TFA) | 98.4% | 795.72 | C36H36F3N9O9 | 10 MG
TO-1187 TFA is a selective PROTAC degrader that targets HDAC6 and recruits cereblon to promote ubiquitination and proteasomal degradation of HDAC6. Supplied as a trifluoroacetic acid salt in solid form, it is intended as a research tool for cellular and preclinical studies investigating HDAC6 biology and PROTAC-mediated target removal.
- Selective HDAC6 degrader with DC50 of 5.81 nM.
- Engages cereblon to induce ubiquitination and proteasomal degradation.
- High chemical purity (98.4%) suitable for biochemical and cellular assays.
- Provided as a solid TFA salt for stable handling and storage.
- Includes analytical documentation such as COA, H NMR, LCMS, and RP-HPLC.
- Storage recommended at 4°C under nitrogen; in solvent store at -80°C (6 months) or -20°C (1 month).
Medchemexpress LLC PF-562271 besylate | 939791-38-5 | MFCD14105612 | 99.2% | 665.66 | C27H26F3N7O6S2 | 10 MG
PF-562271 besylate is the besylate salt of PF-562271, a potent ATP-competitive, reversible inhibitor of focal adhesion kinase (FAK) and Pyk2 used in cancer research to probe signaling pathways, tumor growth, and cell adhesion. The compound is supplied as a high-purity solid for in vitro and in vivo studies.
- Potent inhibition of FAK and Pyk2 (FAK IC50 ~1.5 nM; Pyk2 IC50 ~13 nM).
- High reported purity (99.17%).
- Provided as a solid, off-white to light-yellow material suitable for handling and formulation.
- Demonstrated antiproliferative activity in multiple human cell lines.
- Used for in vitro and in vivo studies of tumor growth, signaling, and angiogenesis.
- Available in a 10 mg package for research use.
Medchemexpress LLC Amlodipine maleate | 88150-47-4 | 99.9% | 5 G
Amlodipine maleate is a dihydropyridine calcium channel blocker that acts as an orally active antianginal agent. It blocks voltage-dependent L-type calcium channels, inhibiting the initial influx of calcium. This compound is used in research for high blood pressure and cancer studies.
- Blocks voltage-dependent L-type calcium channels
- Inhibits initial influx of calcium
- Attenuates uridine 5′-triphosphate (UTP)-induced increases of intracellular calcium
- Inhibits store-operated calcium influx
Apexbio Technology LLC Cisatracurium Besylate 96946-42-8 10mM (in 1mL DMSO)
Cisatracurium Besylate (CAS 96946-42-8) is a non-depolarizing neuromuscular blocking agent that acts by competitively inhibiting acetylcholine at nicotinic receptors on the neuromuscular junction This inhibition prevents depolarization of the muscle cell membrane resulting in skeletal muscle relaxation Cisatracurium Besylate is utilized in biomedical research to study neuromuscular transmission skeletal muscle function and mechanisms underlying muscle paralysis It is also frequently used as an adjunct in anesthesia research to model conditions requiring controlled muscle relaxation such as intubation or mechanical ventilation
Medchemexpress LLC PF-562271 besylate | 939791-38-5 | MFCD14105612 | 99.2% | 665.66 g/mol | C27H26F3N7O6S2 | 1 ML
PF-562271 besylate is a potent, ATP-competitive, reversible inhibitor of focal adhesion kinase (FAK) and Pyk2 used in biochemical, cell-based, and in vivo research. It is supplied as a 10 mM solution in DMSO and exhibits low-nanomolar activity against FAK and nanomolar activity against Pyk2.
- Potent inhibition of FAK and Pyk2 (FAK IC50 = 1.5 nM; Pyk2 IC50 = 13 nM).
- Supplied as a ready-to-use 10 mM solution in DMSO for in vitro assays.
- High reported purity suitable for research use (99.17%).
- Demonstrated antiproliferative activity across multiple cancer cell lines.
- Validated pharmacological effects in vivo, including inhibition of FAK phosphorylation.
Apexbio Technology LLC Amlodipine 88150-42-9 1g
Amlodipine (CAS 88150-42-9) is a dihydropyridine-based small molecule that functions as a long-acting calcium channel blocker It selectively inhibits L-type calcium channels on vascular smooth muscle and cardiac myocytes thereby reducing intracellular calcium influx This action leads to vasodilation and decreased vascular resistance Amlodipine is widely utilized in biomedical research to investigate calcium signaling pathways vascular tone modulation and cardiovascular pharmacology Its mechanistic profile also makes it a reference compound in studies evaluating novel antihypertensive or vasodilatory agents
Apexbio Technology LLC Amlodipine Besylate 111470-99-6 10mM (in 1mL DMSO)
Amlodipine Besylate (CAS 111470-99-6) is a long-acting calcium channel blocker that reduces blood pressure primarily through inhibition of calcium ion influx via voltage-gated calcium channels Calcium channel modulation influences critical cellular signaling pathways In cortical neurons exposed to oxidative stress Amlodipine Besylate ( 5 M) preserves cellular viability by reducing oxidative damage enhancing pro-survival signals and suppressing apoptotic pathways It has also demonstrated proliferative effects on human epidermoid carcinoma (A431) cells Furthermore clinical studies indicate that Amlodipine Besylate decreases peripheral vascular resistance and myocardial oxygen demand in angina patients and effectively lowers arterial pressure in hypertensive feline models
Medchemexpress LLC To-1187 TFA | 98.4% | 795.72 | 100 MG
TO-1187 TFA is a selective HDAC6 PROTAC degrader with a DC50 of 5.81 nM. It functions by promoting the ubiquitination and degradation of HDAC6 and can be used in the study of hematological malignancies and solid tumors. The compound is described as being composed of an HDAC6 ligand (HY-173386), a CRBN ligase ligand (HY-41547), and a linker (HY-140212).
- Selective HDAC6 PROTAC degrader (DC50: 5.81 nM).
- Promotes the ubiquitination and degradation of HDAC6.
- Applicable in the study of hematological malignancies and solid tumors.
Medchemexpress LLC Molibresib (besylate) | 1895049-20-3 | 97.0% | 50 MG
Molibresib besylate is an orally active pan-BET inhibitor that targets BRD2, BRD3, BRD4, and BRDT. It disrupts the interaction between BET proteins and chromatin, inhibiting MYC expression and target gene transcription. This compound exhibits broad antiproliferative activity, inhibiting cancer cell growth and inducing growth arrest. It is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer, and various advanced refractory solid tumors.
- Orally active pan-BET inhibitor.
- Targets BRD2, BRD3, BRD4, and BRDT.
- Inhibits MYC expression and target gene transcription.
- Exhibits broad antiproliferative activity.
- Shows synergistic effect with MEK inhibitors.
- Applicable for research in acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, and small-cell lung cancer.